India, Uzbekistan Launch Pharma–Nutraceutical Trade Corridor to Expand Eurasian Healthcare Market Access
A new India–Uzbekistan corridor aims to streamline pharmaceutical and nutraceutical trade while positioning Uzbekistan as a gateway to CIS markets.
- By PharmaNews Live Desk
- New Delhi
- Mar 09, 2026
India and Uzbekistan have launched a pharmaceutical and nutraceutical trade corridor aimed at strengthening cross-border healthcare commerce and facilitating market access for Indian companies across Central Asia and the Commonwealth of Independent States (CIS).
The initiative has been formalised through cooperation between Uzbekistan’s Ministry of Health and industry platforms working to build a structured trade ecosystem linking South Asia with Eurasian markets. The corridor is expected to support regulatory coordination, supply chain integration, and investment partnerships in pharmaceuticals, nutraceuticals, and related healthcare sectors.
Officials say the move reflects growing economic engagement between India and Central Asia and aims to create a scalable trade architecture for healthcare products in the region.
Pharma Eurasia 2026 to serve as launch platform
The commercial rollout of the corridor will take place during Pharma Eurasia 2026, scheduled to be held in Tashkent from May 20 to 22, 2026. The event is expected to bring together policymakers, manufacturers, regulators, and investors to advance trade partnerships and commercial collaborations.
The platform will act as a marketplace for companies seeking entry into Eurasian healthcare markets and is expected to support networking between Indian exporters and regional distributors.
Focus on regulatory alignment and supply-chain integration
The corridor will focus on strengthening policy coordination and operational frameworks needed for cross-border healthcare trade.
Key areas of cooperation include regulatory harmonisation, digitisation of supply chain documentation, bilateral investment facilitation, and the promotion of joint ventures and research collaboration in pharmaceuticals and nutraceuticals.
The initiative is also expected to support structured business matchmaking and commercial partnerships aimed at accelerating trade between South Asia and the Eurasian region.
Uzbekistan positions itself as gateway to CIS
Uzbek officials say the initiative could reinforce the country’s role as a regional hub linking India with CIS markets.
Abdulla Azizov, First Deputy Minister of Health and Chairman of the Pharmaceutical Industry Development Agency of Uzbekistan, said, “Uzbekistan is poised to emerge as a strategic bridge between India and the CIS in pharmaceuticals and nutraceuticals.”
He added that the collaboration aims to institutionalise “a transparent, technology-enabled trade ecosystem that creates lasting value for stakeholders.”
Kamila Mirzaeva, Chief International Relations Specialist at Uzbekistan’s Ministry of Health, noted that the initiative integrates transparency and digital tools into a more institutionalised trade architecture while encouraging joint ventures, manufacturing cooperation, and technology transfer between partners.
Growing healthcare trade ties
The corridor highlights the expanding economic relationship between India and Uzbekistan, particularly in pharmaceuticals and healthcare manufacturing.
With Indian pharmaceutical companies already active in Central Asian markets, policymakers and industry stakeholders see the new corridor as a mechanism to deepen trade flows, encourage investment partnerships, and strengthen supply chains connecting India with Eurasia’s growing healthcare markets.